Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis.

Abstract

40 patients with American cutaneous leishmaniasis caused primarily by Leishmania braziliensis panamensis were treated with sodium stibogluconate in a double-blind, randomised controlled trial. Nine weeks after starting treatment, all 19 patients treated with 20 mg Sb/kg per day for twenty days were cured but 5 of 21 patients treated with 10 mg Sb/kg per day for twenty days had persistent active disease (p less than 0.05). Both treatment regimens were well tolerated and they were associated with a similar incidence of reversible toxic effects. Existing recommendations for therapy of American cutaneous leishmaniasis with sodium stibogluconate are inadequate for some patients, and higher doses are both safe and efficacious.

• Authors: W R Ballou, J B McClain, D M Gordon, G D Shanks, J Andujar, J D Berman, J D Chulay
• Journal: Lancet (London, England) (Lancet) Vol. 2 Issue 8549 Pg. 13-6 (Jul 04 1987) ISSN: 0140-6736 [Print] England
• PMID: 2885505 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Gluconates
• Antimony Sodium Gluconate

Topics

• Adolescent
• Adult
• Antimony Sodium Gluconate (administration & dosage, adverse effects)
• Clinical Trials as Topic
• Double-Blind Method
• Follow-Up Studies
• Gluconates (administration & dosage)
• Humans
• Joint Diseases (chemically induced)
• Leishmania braziliensis (isolation & purification)
• Leishmania donovani (isolation & purification)
• Leishmaniasis (drug therapy)
• Male
• Military Personnel
• Random Allocation
• Safety